The intricate interconnection between neuropharmacology and neurodegenerative diseases is becoming increasingly evident as research delves deeper into the intricacies of the nervous system. With the approach of Alzheimer's 2024, the upcoming scientific session on this subject holds great potential for uncovering innovative therapeutic strategies and gaining a deeper comprehension of the underlying mechanisms contributing to neurodegeneration.
Central to this discourse is the exploration of pharmacological agents targeting specific molecular pathways associated with Alzheimer's disease. The development of drugs that modulate neurotransmitter systems, regulate protein aggregation, and enhance neuroprotective mechanisms represents a promising avenue for potentially halting or reversing the progression of this debilitating disorder.
The scientific session on neuropharmacology and neurodegenerative diseases at Alzheimer's 2024 is anticipated to serve as a crucial platform for the exchange of groundbreaking discoveries, the cultivation of collaborations, and the advancement of efforts towards effective treatments for Alzheimer's disease and other neurodegenerative conditions.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
